10x Genomics (TXG) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		80,156,104
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		27,450,713

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 768,773	$ 424,166
Restricted cash	59,451	0
Accounts receivable, net	36,026	33,371
Inventory	25,118	15,270
Prepaid expenses and other current assets	11,083	8,033
Total current assets	900,451	480,840
Property and equipment, net	65,111	48,821
Restricted cash	5,474	52,327
Operating lease right-of-use assets	45,379
Other assets	26,129	23,935
Total assets	1,042,544	605,923
Current liabilities:
Accrued contingent liabilities	77,558	0
Accounts payable	9,490	13,028
Accrued compensation and related benefits	11,189	12,394
Accrued expenses and other current liabilities	38,583	24,448
Term loans, current portion	0	9,882
Deferred revenue, current	3,775	3,297
Operating lease liabilities	4,976
Total current liabilities	145,571	63,049
Term loans, noncurrent portion	0	19,837
Accrued contingent liabilities	0	68,658
Accrued license fee, noncurrent	11,223	16,251
Deferred rent, noncurrent		16,120
Operating lease liabilities, noncurrent	56,618
Other noncurrent liabilities	4,052	1,925
Total liabilities	217,464	185,840
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of September 30, 2020 and December 31, 2019	0	0
Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 105,599,976 shares issued and outstanding as of September 30, 2020; 1,100,000,000 shares authorized and 96,241,596 shares issued and outstanding as of December 31, 2019	2	2
Additional paid-in capital	1,214,655	682,494
Accumulated deficit	(389,525)	(262,367)
Accumulated other comprehensive loss	(52)	(46)
Total stockholders’ equity	825,080	420,083
Total liabilities and stockholders’ equity	$ 1,042,544	$ 605,923

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred Stock, Par Value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized (in shares)	1,100,000,000	1,100,000,000
Common Stock, Shares, Issued (in shares)	105,599,976	96,241,596
Common Stock, Shares, Outstanding (in shares)	105,599,976	96,241,596

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 71,817	$ 61,207	$ 186,627	$ 170,604
Cost of revenue	14,411	15,480	39,571	44,451
Gross profit	57,406	45,727	147,056	126,153
Operating expenses:
Research and development	30,143	22,209	83,670	55,208
In-process research and development	40,637	0	40,637	0
Selling, general and administrative	51,549	32,614	146,352	92,078
Accrued contingent liabilities	332	0	956	1,360
Total operating expenses	122,661	54,823	271,615	148,646
Loss from operations	(65,255)	(9,096)	(124,559)	(22,493)
Other income (expense):
Interest income	28	481	1,471	986
Interest expense	(397)	(708)	(1,365)	(2,087)
Other expense (income), net	361	(272)	121	(413)
Loss on extinguishment of debt	0	0	(1,521)	0
Total other expense	(8)	(499)	(1,294)	(1,514)
Loss before provision for income taxes	(65,263)	(9,595)	(125,853)	(24,007)
Provision for income taxes	585	8	1,305	110
Net loss	(65,848)	(9,603)	(127,158)	(24,117)
Other comprehensive income:
Foreign currency translation adjustment	(366)	(126)	(6)	(123)
Comprehensive loss	$ (66,214)	$ (9,729)	$ (127,164)	$ (24,240)
Net loss per share, basic and diluted (in dollars per share)	$ (0.65)	$ (0.33)	$ (1.28)	$ (1.21)
Weighted-average shares of common stock used in computing net loss per share, basic and diluted (in shares)	101,341,945	29,184,218	99,058,139	19,904,184

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Convertible Preferred Stock	Common Class A	Common Class ACommon Stock	Common Class AAdditional Paid-in Capital	Preferred Class B	Common Class B	Common Class BCommon Stock	Common Class BAdditional Paid-in Capital
Beginning balance of temporary equity (in shares) at Dec. 31, 2018						67,704,278
Beginning balance of temporary equity at Dec. 31, 2018						$ 243,244
Beginning balance (in shares) at Dec. 31, 2018		14,549,801
Beginning balance at Dec. 31, 2018	$ (219,987)	$ 1	$ 11,165	$ (231,116)	$ (37)
Issuance of Class A common stock upon exercise of stock options (in shares)								898,858
Issuance of Class A common stock upon exercise of stock options							$ 923		$ 923
Vesting of shares subject to repurchase, including early exercised options	72		72
Stock-based compensation	1,359		1,359
Net loss	(3,636)			(3,636)
Other comprehensive income (loss)	(24)				(24)
Ending balance of temporary equity (in shares) at Mar. 31, 2019						67,704,278
Ending balance of temporary equity at Mar. 31, 2019						$ 243,244
Ending balance (in shares) at Mar. 31, 2019		15,448,659
Ending balance at Mar. 31, 2019	(221,293)	$ 1	13,519	(234,752)	(61)
Beginning balance of temporary equity (in shares) at Dec. 31, 2018						67,704,278
Beginning balance of temporary equity at Dec. 31, 2018						$ 243,244
Beginning balance (in shares) at Dec. 31, 2018		14,549,801
Beginning balance at Dec. 31, 2018	(219,987)	$ 1	11,165	(231,116)	(37)
Net loss	(24,117)
Ending balance of temporary equity (in shares) at Sep. 30, 2019						0
Ending balance of temporary equity at Sep. 30, 2019						$ 0
Ending balance (in shares) at Sep. 30, 2019		96,118,804
Ending balance at Sep. 30, 2019	421,448	$ 2	676,839	(255,233)	(160)
Beginning balance of temporary equity (in shares) at Mar. 31, 2019						67,704,278
Beginning balance of temporary equity at Mar. 31, 2019						$ 243,244
Beginning balance (in shares) at Mar. 31, 2019		15,448,659
Beginning balance at Mar. 31, 2019	(221,293)	$ 1	13,519	(234,752)	(61)
Issuance of Class A common stock upon exercise of stock options (in shares)								696,723
Issuance of Class A common stock upon exercise of stock options							1,082		1,082
Vesting of shares subject to repurchase, including early exercised options	89		89
Stock-based compensation	3,025		3,025
Net loss	(10,878)			(10,878)
Other comprehensive income (loss)	27				27
Ending balance of temporary equity (in shares) at Jun. 30, 2019						67,704,278
Ending balance of temporary equity at Jun. 30, 2019						$ 243,244
Ending balance (in shares) at Jun. 30, 2019		16,145,382
Ending balance at Jun. 30, 2019	(227,948)	$ 1	17,715	(245,630)	(34)
Issuance of Class A common stock upon exercise of stock options (in shares)								508,120
Issuance of Class A common stock upon exercise of stock options							1,013		1,013
Conversion of convertible preferred stock into Class B common stock (in shares)										(67,704,278)		67,704,278
Conversion of convertible preferred stock into Class B common stock										$ (243,244)
Conversion of convertible preferred stock into Class B common stock											$ 243,244	$ 1	$ 243,243
Issuance and sale of Class A common stock net of issuance costs (in shares)								11,500,000
Issuance and sale of Class A common stock net of issuance costs	410,824								410,824
Cashless exercise of Class A common stock warrants (in shares)								261,024
Vesting of shares subject to repurchase, including early exercised options	170		170
Stock-based compensation	3,874		3,874
Net loss	(9,603)			(9,603)
Other comprehensive income (loss)	(126)				(126)
Ending balance of temporary equity (in shares) at Sep. 30, 2019						0
Ending balance of temporary equity at Sep. 30, 2019						$ 0
Ending balance (in shares) at Sep. 30, 2019		96,118,804
Ending balance at Sep. 30, 2019	421,448	$ 2	676,839	(255,233)	(160)
Beginning balance of temporary equity (in shares) at Dec. 31, 2019						0
Beginning balance of temporary equity at Dec. 31, 2019						$ 0
Beginning balance (in shares) at Dec. 31, 2019		96,241,596
Beginning balance at Dec. 31, 2019	420,083	$ 2	682,494	(262,367)	(46)
Issuance of Class A common stock upon exercise of stock options (in shares)								1,903,612
Issuance of Class A common stock upon exercise of stock options							3,283		3,283
Vesting of shares subject to repurchase, including early exercised options	122		122
Stock-based compensation	6,718		6,718
Net loss	(21,143)			(21,143)
Other comprehensive income (loss)	5				5
Ending balance of temporary equity (in shares) at Mar. 31, 2020						0
Ending balance of temporary equity at Mar. 31, 2020						$ 0
Ending balance (in shares) at Mar. 31, 2020		98,145,208
Ending balance at Mar. 31, 2020	409,068	$ 2	692,617	(283,510)	(41)
Beginning balance of temporary equity (in shares) at Dec. 31, 2019						0
Beginning balance of temporary equity at Dec. 31, 2019						$ 0
Beginning balance (in shares) at Dec. 31, 2019		96,241,596
Beginning balance at Dec. 31, 2019	$ 420,083	$ 2	682,494	(262,367)	(46)
Issuance of Class A common stock upon exercise of stock options (in shares)	4,558,286
Net loss	$ (127,158)
Ending balance of temporary equity (in shares) at Sep. 30, 2020						0
Ending balance of temporary equity at Sep. 30, 2020						$ 0
Ending balance (in shares) at Sep. 30, 2020		105,599,976
Ending balance at Sep. 30, 2020	825,080	$ 2	1,214,655	(389,525)	(52)
Beginning balance of temporary equity (in shares) at Mar. 31, 2020						0
Beginning balance of temporary equity at Mar. 31, 2020						$ 0
Beginning balance (in shares) at Mar. 31, 2020		98,145,208
Beginning balance at Mar. 31, 2020	409,068	$ 2	692,617	(283,510)	(41)
Issuance of Class A common stock related to equity awards (in shares)								2,113,974
Issuance of Class A common stock related to equity awards							8,051		8,051
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	13,920		13,920
Net loss	(40,167)			(40,167)
Other comprehensive income (loss)	355				355
Ending balance of temporary equity (in shares) at Jun. 30, 2020						0
Ending balance of temporary equity at Jun. 30, 2020						$ 0
Ending balance (in shares) at Jun. 30, 2020		100,259,182
Ending balance at Jun. 30, 2020	391,269	$ 2	714,630	(323,677)	314
Issuance and sale of Class A common stock net of issuance costs (in shares)								4,600,000
Issuance and sale of Class A common stock net of issuance costs							482,279		482,279
Issuance of Class A common stock related to equity awards (in shares)								740,794
Issuance of Class A common stock related to equity awards							$ 3,920		$ 3,920
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	13,784		13,784
Net loss	(65,848)			(65,848)
Other comprehensive income (loss)	(366)				(366)
Ending balance of temporary equity (in shares) at Sep. 30, 2020						0
Ending balance of temporary equity at Sep. 30, 2020						$ 0
Ending balance (in shares) at Sep. 30, 2020		105,599,976
Ending balance at Sep. 30, 2020	$ 825,080	$ 2	$ 1,214,655	$ (389,525)	$ (52)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities:
Net loss	$ (127,158)	$ (24,117)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	10,094	4,221
Stock-based compensation expense	34,357	8,258
Loss on disposal of property and equipment	0	614
Loss on extinguishment of debt	1,521	0
Accretion of discount on term loan	17	72
Amortization of right-of-use assets	3,511	0
Changes in operating assets and liabilities:
Accounts receivable	(2,654)	1,938
Inventory	(9,848)	(4,735)
Prepaid expenses and other current assets	(3,363)	(2,756)
Other assets	(2,574)	49
Accounts payable	(3,307)	2,686
Accrued compensation and other related benefits	(1,286)	838
Deferred revenue	898	787
Accrued contingent liabilities	8,900	24,501
Accrued expenses and other current liabilities	9,464	2,550
Deferred rent, noncurrent	0	12,841
Operating lease liability	(3,093)	0
Other noncurrent liabilities	(3,202)	180
Net cash (used in) provided by operating activities	(87,723)	27,927
Investing activities:
Acquisition of intangible assets	(801)	0
Purchases of property and equipment	(15,327)	(36,186)
Net cash used in investing activities	(16,128)	(36,186)
Financing activities:
Payments on financing arrangement	(5,846)	0
Payments on term loans	(31,256)	0
Proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs	483,047	412,679
Proceeds from borrowings under revolver	0	11,000
Payments on borrowings under revolver	0	(11,000)
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	15,255	3,018
Net cash provided by financing activities	461,200	415,697
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	(144)	(37)
Net increase in cash, cash equivalents, and restricted cash	357,205	407,401
Cash, cash equivalents, and restricted cash at beginning of period	476,493	70,088
Cash, cash equivalents, and restricted cash at end of period	833,698	477,489
Supplemental disclosures of cash flow information:
Cash paid for interest	1,670	1,722
Cash paid for taxes	224	22
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	14,183	6,511
Right-of-use assets obtained in exchange for new operating lease liabilities	10,883	0
Deferred offering costs in accounts payable and accrued expenses and other current liabilities	768	1,855
Conversion of convertible preferred stock into common stock upon initial public offering	$ 0	$ 243,244

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012 and is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium and Chromium Connect instruments, which the Company refers to as “instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for both the Company’s Visium and Chromium solutions, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in China, Germany, Netherlands, Singapore, Sweden and the United Kingdom. Initial Public Offering The Company’s registration statement on Form S-1 related to its initial public offering (“IPO”) was declared effective on September 11, 2019 by the Securities and Exchange Commission (“SEC”), and the Company’s Class A common stock began trading on the Nasdaq Global Select Market on September 12, 2019. On September 16, 2019, the Company completed its IPO, in which the Company sold 11,500,000 shares of Class A common stock (which included 1,500,000 shares that were offered and sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares) at a price to the public of $39.00 per share. Including the option exercise, the Company received aggregate net proceeds of $410.8 million after deducting offering costs, underwriting discounts and commissions of $37.7 million. Follow-on Public Offering The Company’s registration statement on Form S-1 related to its follow-on public offering was declared effective by the SEC on September 10, 2020. The Company sold 4,600,000 shares of Class A common stock (which included 600,000 shares that were offered and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) at a price to the public of $110.00 per share. Including the option exercise, the Company received aggregate net proceeds of $482.2 million after deducting offering costs, underwriting discounts and commissions of $23.8 million. Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2019 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2019 included in the Annual Report on Form 10-K filed with the SEC on February 27, 2020. Certain immaterial reclassifications were made to the prior year financial statements to conform to the current period presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies During the three and nine months ended September 30, 2020, there have been no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, except as described below under “Recently Adopted Accounting Pronouncements.” Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Cash and cash equivalents are comprised of money market funds and cash. Money market funds are highly liquid investments which are actively traded and are comprised of United States government securities. The pricing information for the Company’s money market funds is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. As of September 30, 2020 and December 31, 2019, the Company held $717.7 million and $398.5 million in money market funds, respectively, with no unrealized gains or losses. Leases The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company gives consideration to its credit risk, term of the lease and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and costs of goods sold over the reasonably assured lease term. The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less. Internal-Use Software The Company capitalizes costs incurred to develop internal-use software within fixed assets and commencing from the first quarter of 2020, began capitalizing costs to develop hosting arrangements within other assets in the condensed consolidated balance sheets. Costs incurred during the preliminary planning and evaluation and post implementation stages of the project are expensed as incurred. Costs incurred during the application development stage of the project are capitalized. These costs are amortized on a straight-line basis over the estimated useful life of the asset. Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no impairment losses recorded for the three and nine-month periods ended September 30, 2020 and 2019. Revenue Recognition Commencing on January 1, 2019, the Company recognized revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers. The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The Company began shipping its Chromium Connect instrument during the first quarter of 2020. The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Stock-Based Compensation The Company’s stock-based compensation relates to stock options, restricted stock units (“RSUs”) and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). Stock-based compensation expense for its stock-based awards are based on their grant date fair value. The Company determines the fair value of RSUs based on the closing value of its stock price listed on Nasdaq at the date of the grant. The Company estimates the fair value of stock option awards granted to employees and directors on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, the Company calculated the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to its IPO and limited publicly available stock price information subsequent to its IPO and therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award. Stock-based compensation expense for nonemployee stock options is measured based on fair market value using the Black-Scholes option pricing model and is recorded as the options vest. Prior to January 1, 2019, nonemployee stock options subject to vesting were revalued periodically over the requisite service period, which was generally the same as the vesting term of the award. From January 1, 2019, the grant date fair market value of nonemployee stock options is recognized in the condensed consolidated statements of operations on a straight-line basis over the requisite service period and forfeitures are recognized as they occur. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. The Company’s participating securities included the Company’s convertible preferred stock, as the holders would have been entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend was paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities, including convertible preferred stock, awards under the Company’s equity compensation plan and common stock warrants. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-2, Leases (Topic 842) . This standard requires substantially all leases to be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. On January 1, 2020, the Company early adopted Topic 842 using the optional transition method by recognizing a cumulative effect adjustment to the opening balance of accumulated deficit as of that date. Results for the three and nine months ended September 30, 2020 are presented under the guidance in Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 – Leases . The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification and to not reassess initial direct costs. Adoption of Topic 842 resulted in the recognition of operating lease right-of-use assets and operating lease liabilities of approximately $38.0 million and $53.8 million, respectively, on the Company’s condensed consolidated balance sheet as of January 1, 2020. The adoption of the new standard did not have an impact on the Company’s beginning accumulated deficit, statement of operations or cash flows. The following table summarizes the impact of Topic 842 on our condensed consolidated balance sheet as of January 1, 2020 (in thousands): December 31, Adjustments due to January 1, 2020 Assets: Operating lease right-of-use assets $ — $ 38,005 $ 38,005 Prepaid expenses and other current assets 8,033 (434) 7,599 Total assets $ 8,033 $ 37,571 $ 45,604 Liabilities: Accrued expenses and other current liabilities $ 24,448 $ (99) $ 24,349 Operating lease liabilities — 3,086 3,086 Deferred rent, noncurrent 16,120 (16,120) — Operating lease liabilities, noncurrent — 50,704 50,704 Total liabilities $ 40,568 $ 37,571 $ 78,139 The adjustments due to the adoption of Topic 842 related to the recognition of operating lease right-of-use assets and operating lease liabilities for the Company’s existing operating leases. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326) , which requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and provides that credit losses relating to available-for-sale debt securities and accounts receivable should be recorded through an allowance for credit losses. The guidance was amended through various ASUs subsequent to ASU 2016-13. The Company calculates the allowance for credit losses as a percentage of the trade accounts receivable balance based on collection history and current economic trends that we expect will impact the level of credit losses over the life of our receivables. The allowance is re-evaluated on a regular basis and adjusted, as required. Trade accounts receivable are considered past due based on the contractual payment terms. Once a trade account receivable is deemed uncollectible, it is charged against this allowance. The Company early adopted this standard on a modified retrospective basis effective January 1, 2020. The adoption did not have a material impact on the condensed consolidated financial statements. In November 2019, the FASB issued ASU 2019-8, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) , which expands the scope of ASC Topic 718 to provide guidance for share-based payment awards granted to a customer in conjunction with selling goods or services accounted for under Topic 606. The Company early adopted this standard on January 1, 2020, which did not have a material impact on the condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Subtopic 350-40) – Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract , which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. The Company early adopted this standard on a prospective basis effective January 1, 2020. As a result of the adoption of this standard, during the three and nine months ended September 30, 2020, the Company capitalized $0.1 million and $2.8 million, respectively, of implementation costs for enterprise resource planning and related software, Oracle Cloud, which went live during the third quarter of 2020. These costs are recorded within other assets in the condensed consolidated balance sheets and amortized on a straight-line basis over its useful life. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) , which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021. The Company is currently evaluating this standard and the impact it may have on the Company’s condensed consolidated financial statements.

Asset Acquisition

Asset Acquisition	9 Months Ended
	Sep. 30, 2020
Asset Acquisition [Abstract]
Asset Acquisition	Asset Acquisition On August 21, 2020, the Company purchased all of the outstanding shares of CartaNA AB (“CartaNA”), a privately held company based in Stockholm, Sweden, for $41.8 million, inclusive of $0.6 million of transaction costs and net of cash acquired of $1.5 million. CartaNA is developing In Situ RNA analysis technology, consisting of a suite of proprietary reagents, which aims to enable researchers to visualize spatially resolved RNA expression profiles with sub-cellular resolution throughout fresh frozen or formalin-fixed, paraffin-embedded tissue sections. The transaction was accounted for as an asset acquisition. In connection with this acquisition, the Company acquired an in-process research and development intangible asset of $40.6 million which did not have alternative future use and therefore was recognized as an expense during the three months ended September 30, 2020 and included as a component of in-process research and development in the consolidated statements of operations and comprehensive loss. The Company also acquired $0.8 million in intangible assets related to customer relationships and assembled workforce which are included in other assets in the condensed consolidated balance sheets. The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process research and development $ 40,637 Intangible assets 801 Other assets and liabilities, net 348 Total net assets acquired $ 41,786

Other Financial Statement Infor

Other Financial Statement Information	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Inventory Inventory was comprised of the following as of the dates indicated (in thousands): September 30, December 31, Purchased materials $ 7,733 $ 6,436 Work in progress 8,475 3,996 Finished goods 8,910 4,838 Inventory $ 25,118 $ 15,270 Intangible Assets, Net Intangible assets, net, which are recorded within other assets in the condensed consolidated balance sheets, consisted of the following (dollars in thousands): September 30, 2020 December 31, 2019 Remaining Useful Life in Years Gross Accumulated Intangibles, Remaining Useful Life in Years Gross Accumulated Intangibles, Technology licenses 14.0 $ 22,504 $ (1,590) $ 20,914 14.7 $ 22,504 $ (440) $ 22,064 Customer relationships 4.1 805 (66) 739 5.9 204 (32) 172 Trademarks 1.1 204 (125) 79 1.9 204 (74) 130 Assembled workforce 4.9 200 (3) 197 — — — Total intangible assets, net $ 23,713 $ (1,784) $ 21,929 $ 22,912 $ (546) $ 22,366 The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2020 (excluding the nine months ended September 30, 2020) $ 455 2021 1,815 2022 1,753 2023 1,723 2024 1,642 Thereafter 14,541 Total $ 21,929 Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures and asset impairments, among other factors. Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued payroll and related costs $ 1,146 $ 470 Employee stock purchase program liability 2,614 1,862 Accrued bonus 2,174 6,154 Accrued commissions 2,412 2,473 Accrued acquisition-related compensation 1,481 818 Other 1,362 617 Accrued compensation and related benefits $ 11,189 $ 12,394 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued legal expenses $ 9,984 $ 4,375 Accrued license fee 5,884 6,183 Accrued royalties for licensed technologies 1,811 2,025 Accrued property and equipment 11,874 3,885 Accrued consulting 2,364 1,173 Product warranties 337 467 Customer deposits 1,100 1,304 Taxes payable 1,788 1,087 Other 3,441 3,949 Accrued expenses and other current liabilities $ 38,583 $ 24,448 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): September 30, December 31, Beginning of period $ 467 $ 804 Amounts charged to cost of revenue 438 741 Repairs and replacements (568) (1,078) End of period $ 337 $ 467 Revenue and Deferred Revenue As of September 30, 2020, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of Chromium instruments, was $5.0 million, of which approximately 75% is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $5.0 million and $4.1 million as of September 30, 2020 and December 31, 2019, respectively, consisted of deferred revenue related to extended warranty service agreements, and as of September 30, 2020, the short-term portion was $3.8 million. Revenue recorded during the three and nine months ended September 30, 2020 included $0.7 million and $2.8 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2019. Contract assets as of September 30, 2020 and December 31, 2019 were not material. The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Instruments $ 9,676 $ 10,377 $ 26,108 $ 25,527 Consumables 60,557 49,745 156,149 142,134 Services 1,584 1,085 4,370 2,943 Total revenue $ 71,817 $ 61,207 $ 186,627 $ 170,604 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 North America $ 42,363 $ 35,838 $ 102,356 $ 97,293 Europe, Middle East and Africa 15,497 12,136 40,370 36,634 China 8,689 7,046 27,314 22,453 Asia-Pacific 1 5,268 6,187 16,587 14,224 Total revenue $ 71,817 $ 61,207 $ 186,627 $ 170,604 1 Asia-Pacific excludes China which is disclosed separately. Revenue for the United States, which is included in North America in the table above, was 57% and 57% of consolidated revenue for the three months ended September 30, 2020 and 2019, respectively, and 53% and 55% of consolidated revenue for the nine months ended September 30, 2020 and 2019, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	Debt In September 2016, the Company entered into a Second Amended and Restated Loan and Security Agreement with Silicon Valley Bank (as amended and restated in February 2018 and as further amended, restated or supplemented from time to time, the “Loan and Security Agreement”), which included a term loan and revolving line of credit. On February 20, 2020, the Company prepaid the remaining balance of the term loan and all associated costs. The final payment of $30.5 million included $28.3 million for the outstanding principal balance of the term loan, $1.8 million for an end of term payment, $0.3 million for early termination fees and $0.1 million for interest. The prepayment resulted in a loss on extinguishment of debt of $1.5 million. The non-accreted portion of the end of term payment, unamortized discounts and early termination fees were included in the calculation of the loss on extinguishment of debt. The revolving line of credit continued to be in effect until its termination at the election of the Company on June 18, 2020. Prior to its termination, the revolving line of credit provided the Company with credit of up to $25.0 million through December 2022. The amount available on the revolving line of credit was based on 80% of eligible receivables and was subject to a borrowing base calculation. Principal amounts outstanding under the revolving line of credit accrued interest at a floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 0.25% or 4.5% and were repayable monthly. Upon termination of the revolving line of credit and the Loan and Security Agreement on June 18, 2020, the Company incurred termination fees of $0.3 million. As of September 30, 2020 and December 31, 2019, there were no balances outstanding under the revolving line of credit.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements The Company leases office, laboratory, manufacturing, distribution and server space with lease terms ranging from 2 to 11 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The Company performed evaluations of these contracts and determined them to be operating leases. For the three and nine months ended September 30, 2020, the Company incurred $2.1 million and $6.1 million, respectively, of operating lease costs. The Company also incurred $19 thousand and $0.2 million, respectively, of variable lease costs for the three and nine months ended September 30, 2020. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. Cash paid for amounts included in the measurement of operating lease liabilities for the nine months ended September 30, 2020 was $5.1 million and was included in net cash used in operating activities in the Company’s condensed consolidated statements of cash flows. The maturity of the Company’s operating lease liabilities as of September 30, 2020 is as follows (in thousands): Operating Leases 2020 (excluding the nine months ended September 30, 2020) $ 1,285 2021 9,106 2022 8,136 2023 8,262 2024 8,015 Thereafter 42,681 Total lease payments $ 77,485 Less: imputed interest (15,987) Present value of operating lease liabilities $ 61,498 Operating lease liabilities, current $ 4,955 Operating lease liabilities, noncurrent $ 56,543 The following table summarizes additional information related to operating leases as of September 30, 2020: Weighted-average remaining lease term: Operating leases 8.7 years Weighted-average discount rate: Operating leases 5.2 % The Company’s future undiscounted lease payments under operating leases (as defined by prior guidance) as of December 31, 2019 are as follow (in thousands): Rent Payments 2020 $ 6,247 2021 7,581 2022 6,794 2023 6,947 2024 7,064 Thereafter 38,346 Total minimum lease payments $ 72,979 Purchase of Land On August 10, 2020, the Company entered into an Agreement for Purchase and Sale (the “Purchase Agreement”) with Equity One (West Coast Portfolio) LLC, a Florida limited liability company (“Seller”), for the potential acquisition of certain real property located in Pleasanton, California (the “Property”) for an aggregate cash purchase price of $29.8 million. The Company had 74 days following the execution of the Purchase Agreement to conduct due diligence on the property (the “Contingency Period”) during which time the Company could have delivered a notice of termination to the Seller if the Company had determined through its due diligence that the Property was not suitable for purchase by the Company. On October 15, 2020, the Contingency Period was extended by 14 days. Prior to the expiration of the extended Contingency Period, the Company sent a Notice of Satisfaction to the Seller waiving the contingencies and provided an additional deposit of $0.8 million to the Seller. Subject to the conditions of the Purchase Agreement, the closing of the sale will occur within 31 days after the expiration of the Contingency Period, unless the Company provides written notice to the Seller and provides a deposit to extend the date of closing for an additional 30 days. The Company intends to utilize this site to accommodate its future growth requirements. Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. Amongst other matters, the Company is currently a defendant in the lawsuits and proceedings described below. In these matters, the plaintiffs are seeking damages and injunctions of sales of the Company's products amongst other remedies. Other than with respect to the 2015 Delaware Action, losses are not probable or estimable for the lawsuits and proceedings described below. The 2015 Delaware Action In February 2015, Raindance Technologies, Inc. (“Raindance”) and the University of Chicago filed suit against the Company in the U.S. District Court for the District of Delaware (the “Delaware Court”), accusing the Company’s legacy GEM products of infringing certain U.S. patents owned by or exclusively licensed to Raindance (the “2015 Delaware Action”). In May 2017, Bio-Rad Laboratories, Inc. (“Bio-Rad”) was substituted as the plaintiff following its acquisition of Raindance. A jury trial was held in November 2018. The jury found that the accused legacy GEM products infringed U.S. Patent Nos. 8,304,193, 8,329,407 and 8,889,083. The jury also concluded that the Company's infringement was willful and awarded Bio-Rad approximately $24 million in damages through June 30, 2018. The Company appealed the jury verdict. Post-trial, Bio-Rad moved for a permanent injunction, treble damages for willful infringement, attorneys’ fees, supplemental damages for the period from the second quarter of 2018 through the end of the trial as well as pre- and post-judgment interest. In response to the jury award, the Company established an accrual of $30.6 million as of December 31, 2018, which was recorded as an operating expense on the condensed consolidated statement of operations for the year ended December 31, 2018. Additionally, beginning in the fourth quarter of 2018, the Company also began recording an accrual for estimated royalties to Bio-Rad as a cost of revenue on the condensed consolidated statements of operations based on an estimated royalty rate of 15% of sales of the Company’s Chromium instruments operating its legacy GEM microfluidic chips and associated consumables. As a result, the Company recorded $7.4 million of royalties for the fourth quarter of 2018. As of December 31, 2018, the Company recorded a total accrual of $38 million related to this matter which represented the jury award plus the Company’s estimate of additional damages for the period from June 30, 2018 to the trial date in November 2018 and the royalties accrued in the fourth quarter of 2018. In July 2019, the Court awarded supplemental damages for the period from June 30, 2018 through the end of the trial in November 2018 and established the interest rates for pre- and post-judgment interest, which when combined with the original award, resulted in a $35 million preliminary judgment in favor of Bio-Rad for damages through November 2018 and interest. During the three and nine months ended September 30, 2020 and 2019, the Company recorded royalties of $2.0 million and $7.9 million, and $7.2 million and $23.1 million respectively, as a cost of revenue and an additional $0.3 million and $0.9 million, and zero and $1.4 million, respectively, during the three and nine months ended September 30, 2020 and 2019, as an operating expense for estimated pre- and post-judgment interest. The Company’s accrual of $77.6 million as of September 30, 2020 is comprised of the preliminary judgment, along with the Company’s estimate of additional royalties and interest for the period from November 2018 through September 30, 2020. To date the Company has not made any payments related to the judgment or royalties. In July 2019, the Court denied Bio-Rad’s other post-trial requests such as attorneys’ fees and enhanced damages for willful infringement. In July 2019, the Court also granted Bio-Rad a permanent injunction against the Company’s legacy GEM microfluidic chips and associated consumables that were found to infringe the Bio-Rad patents, which historically constituted a significant amount of the Company’s product sales. However, under the injunction, the Company is permitted to continue to sell its legacy GEM microfluidic chips and associated consumables for use with its historical installed base of instruments provided that the Company pay into escrow a royalty of 15% of the Company’s net revenue related to such sales occurring after August 28, 2019. The amounts will be held in escrow until after the conclusion of the Company’s Federal Circuit appeal and the Delaware Court addresses anticipated motions regarding post-judgment royalties. In August 2019, the Court ordered that the Company may post a bond in the amount of $52 million in lieu of payment of the final judgment. Bio-Rad subsequently asked the Court to increase the amount of the bond to approximately $61 million. The Company also asked the Court to reconsider its ruling and decrease the potential bond to approximately $35 million. On September 13, 2019, the Company posted a $52 million bond (the “Bond”) in lieu of payment of the judgment pending the Company’s ongoing appeal. In connection with the Bond, the Company deposited $45 million as collateral in a segregated cash account. On October 10, 2019, the Court denied the Company’s motion to decrease the bond amount, and, without addressing Bio-Rad’s request to increase the bond amount, stayed any execution or enforcement of the judgment until the completion of appeal, and for thirty days thereafter. The Company appealed the Court's judgment including the injunction to the Federal Circuit. In August 2020, the Federal Circuit issued its opinion in the Company's appeal of the 2015 Delaware Action. The Federal Circuit (1) affirmed the judgment of the lower Court with respect to infringement of the '083 patent by the Company's legacy GEM products and (2) vacated the judgment with respect to infringement of the '193 and '407 patents, which are remanded to the lower Court for a new trial on infringement. The Federal Circuit affirmed the damages award including the 15% royalty with respect to the Company's legacy GEM products. The Federal Circuit vacated the injunction with respect to the Company's Single Cell CNV and Linked-Read products but affirmed the injunction with respect to the Company's other legacy GEM products. In October 2020, the Company filed a petition for en banc rehearing with the Federal Circuit. The Federal Circuit denied the Company's petition for en banc rehearing on November 4, 2020 and is expected to issue a mandate in November 2020. The Company expects the $34.5 million judgment, plus approximately $0.8 million in post-judgment interest, to be payable to Bio-Rad in December 2020. The Company further expects the case will be remanded to the Delaware Court for a determination of post-judgment royalties or other amounts, which the Company expects to be made in the first half of 2021. The Company has accrued $77.6 million as of September 30, 2020 related to this matter which is classified within current liabilities in its condensed consolidated balance sheets as of this date. Restricted cash of $59.4 million, classified within current assets in the Company's condensed consolidated balance sheets as of September 30, 2020 serves as collateral for a bond and royalties in connection with the Bio-Rad litigation and would be used to partially satisfy this payment. The ITC 1068 Action On July 31, 2017, Bio-Rad and Lawrence Livermore National Security, LLC filed a complaint against the Company in the U.S. International Trade Commission (“ITC”) pursuant to Section 337 of the Tariff Act of 1930, accusing substantially all of the Company’s Chromium products of infringing certain asserted patents (the “ITC 1068 Action”). In September 2018, the judge found that the Company’s legacy GEM microfluidic chips infringe certain of the asserted patents, but also that the Company’s gel bead manufacturing microfluidic chip and Next GEM microfluidic chip do not infringe any claim asserted against them (the “Initial Determination”). The judge recommended entry of an exclusion order preventing the Company from importing its legacy GEM microfluidic chips and a cease and desist order that would prevent the Company from selling such imported chips. On December 18, 2019, the ITC issued its final determination in the ITC 1068 Action (the “Final Determination”). The Final Determination affirmed the Initial Determination that the Company’s Next GEM microfluidic chips and gel bead manufacturing microfluidic chips do not infringe any of the claims asserted against them. The Final Determination also affirmed the ruling that the Company’s legacy GEM microfluidic chips infringe the ‘664, ‘682 and ‘635 patents but not the ‘160 patent. The ITC issued (1) a limited exclusion order prohibiting the unlicensed importation of the legacy GEM microfluidic chips into the United States and (2) a cease and desist order preventing the Company from selling such imported legacy GEM microfluidic chips in the United States. The ITC expressly allowed the importation and sale of the legacy GEM microfluidic chips for use by researchers who were using such chips as of December 18, 2019, and who have a documented need to continue receiving such chips for a specific current ongoing research project for which that need cannot be met by any alternative product. The Final Determination was subject to a 60-day presidential review period. During the presidential review period, the Company was permitted to continue importation and sales of the legacy GEM microfluidic chips subject to payment of a bond of three (3) percent of the entered value of the accused microfluidic chips. The Company and Bio-Rad have appealed the Final Determination to the Court of Appeals for the Federal Circuit. Bio-Rad has appealed the Final Determination with respect to non-infringement of the Company's gel bead manufacturing chips, but not with respect to non-infringement of the Company's Next GEM microfluidic chips. The Company has appealed the Final Determination with respect to infringement of the Company's legacy GEM microfluidic chips. The Company expects oral arguments to be held around the first quarter of 2021 and a decision around mid-2021. The Northern District of California Action On July 31, 2017, Bio-Rad and Lawrence Livermore National Security, LLC also filed suit against the Company in the U.S. District Court for the Northern District of California, alleging that the Company’s legacy GEM products infringe certain patents in addition to the patents asserted in the ITC 1068 Action. The complaint seeks injunctive relief, unspecified monetary damages, costs and attorneys’ fees. This litigation has been stayed pending resolution of the Federal Circuit appeal of the ITC 1068 Action. In July 2020, Bio-Rad moved to lift the stay with respect to the '059 patent and consolidate the '059 patent with the '115 patent transferred from the District of Massachusetts which is being asserted against the Company's Next GEM products. In August 2020, the Court denied Bio-Rad's motion to lift the stay with respect to both the '059 and '115 patents. In October 2020, we filed two petitions for inter partes review (“IPR”) challenging the validity of the ‘115 patent. We expect the Patent Trials and Appeals Board (“PTAB”) to issue a decision on institution of these IPR petitions in the second quarter of 2021. The Company believes that this lawsuit is without merit and intends to vigorously defend itself. The Germany Action On July 31, 2017, Bio-Rad filed suit against the Company in Germany in the Munich Region Court alleging that the Company infringed a European patent. Bio-Rad dismissed this action in August 2018. On February 13, 2018, Bio-Rad filed suit against the Company in Germany in the Munich Region Court alleging that its Chromium instruments, legacy GEM microfluidic chips and certain accessories infringe a German utility model. Bio-Rad seeks unspecified damages and an injunction prohibiting sales of these products in Germany and requiring the Company to recall these products sold in Germany subsequent to February 11, 2018. An initial hearing was held on November 27, 2018, and a subsequent hearing was held on May 15, 2019. The Court issued a ruling on November 20, 2019. The Court ruled that the Company’s legacy GEM microfluidic chips, as well as certain Chromium instruments and accessories used with legacy GEM microfluidic chips, infringed the German Utility Model. The Court issued an injunction with respect to such legacy GEM microfluidic chips, Chromium instruments and accessories used with such systems, prohibiting among other things the sale of these products in Germany and the importation of such products into Germany. The Court found that the Company is obligated to compensate Bio-Rad for unspecified damages and required that these products be recalled from distribution channels in Germany. The Court further found that the Company has to bear the statutory costs of the legal dispute in a minimum amount of at least 61,000 Euros. The Company has accrued the 61,000 Euros for statutory costs in the condensed consolidated balance sheet as of September 30, 2020. The Company is unable to estimate any additional potential exposure related to the matter beyond the statutory costs that have been accrued. The Court’s ruling did not address the Company’s Next GEM products, which were not accused in this action and which constitute substantially all of the Company’s Chromium sales in Germany. The Company appealed the Court’s ruling. On April 6, 2020, the Munich Higher Regional Court (the “Higher Court”) issued a ruling staying enforcement of the ruling of the lower Court, including the injunction, subject to the payment of a bond by the Company. The Higher Court found that the lower Court’s claim construction was not justifiable and that the facts did not provide a basis for a finding of infringement. On April 16, 2020, the Company paid a 2.8 million Euro bond to the Higher Court to completely stay enforcement of the ruling. The bond is refundable upon a favorable ruling on the merits by the Higher Court. The Company expects the Higher Court to rule on the merits in 2021. In August 2020, Bio-Rad filed its appeal response arguing for the first time that the Company's Next GEM microfluidic chips and certain accessories infringe the utility model. In its appeal response, Bio-Rad also attempted to add infringement allegations with respect to a new patent, European Patent No. 3 132 844, against the Company's Chromium instruments and Next GEM microfluidic chips. The Company believes it is procedurally improper to attempt to add these new claims at this stage, that the Company's Next GEM products are not covered by the lower court's judgment and are not admissible in the appeal, and that the newly asserted '844 patent is not admissible in the appeal. The Higher Court is not expected to rule on whether Next GEM products or the '844 patent are admissible in the appeal until 2021. The 2018 Delaware Action On October 25, 2018, Bio-Rad filed suit against the Company in the U.S. District Court for the District of Delaware alleging that substantially all of the Company’s Chromium products, including our legacy GEM products and Next GEM products, infringe U.S. Patent Nos. 9,562,837 and 9,896,722. Bio-Rad seeks injunctive relief, unspecified monetary damages, costs and attorneys’ fees. In October 2019, the Company filed four petitions for IPR challenging the validity of both asserted patents. On April 27, 2020, the PTAB instituted review on all four of these petitions. A final written decision is expected from the PTAB in April 2021. In June 2020, the Court completely stayed the District of Delaware litigation pending resolution of the IPRs before the PTAB. The Massachusetts Action On September 11, 2019, Bio-Rad filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company’s Next GEM products infringe certain claims of U.S. Patent No. 8,871,444. On November 5, 2019, Bio-Rad amended the complaint to additionally allege that the Company’s Next GEM products infringe certain claims of U.S. Patent Nos. 9,919,277 and 10,190,115. The ‘444 and ‘277 patents are exclusively licensed by Bio-Rad from Harvard University, which subsequently joined the suit as a party plaintiff. Bio-Rad is seeking damages and an injunction against the Company's Next GEM products amongst other remedies. The ‘444 and ‘277 patents are projected to expire in October 2024. On December 18, 2019, Bio-Rad dismissed this action in the District of Delaware and refiled it in the U.S. District Court for the District of Massachusetts. The case was assigned to Judge William G. Young. On January 14, 2020, the Court consolidated this case with a separate action, Bio-Rad Laboratories Inc. et al. v. Stilla Technologies, Inc. (“Stilla”), in which Bio-Rad is asserting the ‘444 patent (among other patents) against Stilla’s droplet digital PCR product. On January 23, 2020, the Company filed a motion to dismiss the case and to transfer the ‘115 patent to the Northern District of California, where the related ‘059 patent is stayed. On January 24, 2020, the Company filed antitrust counterclaims against Bio-Rad alleging violations of (a) Section 7 of the Clayton Act, (b) Section 2 of the Sherman Act and (c) California unfair competition laws, for illegally acquiring Raindance and illegally monopolizing or attempting to monopolize markets relating to droplet digital PCR products, droplet single cell products and droplet genetic analysis technology. On February 19, 2020, Bio-Rad moved to dismiss, or alternatively to stay and sever, the Company’s antitrust claims. On February 5, 2020, the Company filed additional counterclaims against Bio-Rad alleging that Bio-Rad’s single cell ATAC-seq products infringe U.S. Patent No. 9,029,085 and 9,850,526 that are exclusively licensed to the Company from Harvard University. On February 26, 2020, Bio-Rad moved to sever and stay the patent counterclaims. On March 6, 2020, the Court denied the motion to stay and deferred the motion to sever until prior to trial. On March 25, 2020, the Court held a hearing with respect to (a) the Company’s motion to dismiss Bio-Rad’s patent claims, (b) the Company’s motion to transfer the ‘115 patent and (c) Bio-Rad’s motion to dismiss the Company’s antitrust counterclaims. On April 30, 2020, the Court denied the Company’s motion to dismiss with respect to Bio-Rad’s patent claims and granted the Company’s motion to transfer the ‘115 patent to the Northern District of California. In August 2020, the Court granted Bio-Rad’s motion to dismiss (i) the Company's Sherman Act and Clayton Act counterclaims with respect to droplet single cell products and (ii) the Company's Sherman Act counterclaims with respect to droplet genetic analysis technology. The Court denied Bio-Rad’s motion to dismiss (i) the Company's Clayton Act counterclaims with respect to droplet genetic analysis technology; (ii) the Company's Sherman Act and Clayton Act counterclaims with respect to droplet digital PCR products; and (iii) the Company's California unfair competition counterclaims. Discovery is ongoing. A Markman hearing was conducted in September 2020. In July 2020, the Court set a trial date for Bio-Rad's patent claims and the Company's patent counterclaims in April 2021 and set a trial date for the Company's antitrust counterclaims in July 2021. In June 2020, the Company filed two petitions for IPR challenging the validity of the '444 patent. In August 2020, the Company filed two petitions for IPR challenging the validity of the '277 patent. The Company expects the PTAB to issue a decision on institution of these IPR petitions in the first quarter of 2021. 2019 Becton Dickinson Settlement and Patent Cross License Agreement On November 15, 2018, Becton, Dickinson and Company (“BD”) and Cellular Research, Inc. filed suit against the Company in the U.S. District Court for the District of Delaware, alleging that the Company infringed certain patents. In September 2019, the Company filed counterclaims alleging that BD and Cellular Research, Inc. (together, the “BD Entities”) infringed a number of the Company’s patents. In October 2019, the Company entered into a settlement and patent cross license agreement (the “BD Agreement”) with the BD Entities. The BD Agreement resolved all outstanding patent litigation between the parties (the “BD Litigation”), which was dismissed with prejudice on October 21, 2019. Under the terms of the BD Agreement, the BD Entities granted the Company and its affiliates, and the Company granted BD and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to molecular barcoding and single cell analysis, including to all the patents asserted in the BD Litigation. The Company is required to make an aggregate payment of $25.0 million to BD in annual amounts of $6.25 million over four years beginning in January 2020 in connection with the BD Agreement. Upon execution of the BD Agreement, the fair value of these payments was recognized as a liability and is classified as accrued expenses and other current liabilities and accrued license fee, noncurrent on the Company’s condensed consolidated balance sheet as of September 30, 2020. As part of the BD Agreement, each party, on behalf of itself and its affiliates, has also entered into a covenant not to sue in certain fields related to each company’s products. The companies have also agreed on behalf of themselves and their affiliates to refrain from challenging the patents and patent applications licensed under the BD Agreement. The Company considers this matter closed. For certain of the Company’s litigation matters, the Company is required to make milestone payments to the Company’s legal counsel based on certain litigation outcomes. Based on the occurrence in the first quarter of 2020 of one such milestone in one of the Company’s litigation matters, a milestone payment to the Company’s legal counsel in the amount of $5 million was triggered in the first quarter of 2020. The Company expects to trigger additional such milestone payments during the pendency of litigation, though the timing and amounts of such payments is uncertain.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Capital Stock	Capital StockAs of September 30, 2020, Class A common stock and Class B common stock issued and outstanding was 77,888,613 shares and 27,710,713 shares, respectively. During the three and nine months ended 2020, 2,153,783 and 47,558,717, respectively, shares of Class B common stock were converted to shares of Class A common stock upon the election of the holders of such shares.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans Amended and Restated 2012 Stock Plan As of September 30, 2020, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan which includes shares issuable upon the exercise of outstanding awards was 10,510,200. Following the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the Amended and Restated 2012 Stock Plan continue to be governed by their existing terms but no further awards may be granted under the Amended and Restated 2012 Stock Plan. 2019 Omnibus Incentive Plan A total of 11,000,000 shares of Class A common stock was reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019. As of September 30, 2020, the number of shares of Class A common stock available for issuance under the 2019 Omnibus Incentive Plan was 3,086,238 shares issuable in connection with outstanding awards and 8,294,784 shares reserved for issuance in connection with grants of future awards. 2019 Employee Stock Purchase Plan A total of 2,000,000 shares of Class A common stock was reserved for issuance under the ESPP at the time the ESPP was adopted in 2019. The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. Shares purchased under the ESPP are subject to a one-year holding period following the purchase date. During the nine months ended September 30, 2020, 118,218 shares of Class A common stock were issued under the ESPP. No shares of Class A common stock were issued under the ESPP during 2019 or during the three months ended September 30, 2020. As of September 30, 2020, there were 1,881,782 shares available for issuance in connection with the current and future offering periods under the ESPP. The assumptions used and the resulting weighted-average fair value per share for stock purchased under the ESPP during the nine months ended September 30, 2020 were as follows: Risk-free interest rate 1.85 % Expected volatility 52.18 % Expected term (years) 0.67 Expected dividends 0 % Weighted average grant-date fair value per share $12.60 Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Cost of revenue $ 398 $ 81 $ 1,108 $ 171 Research and development 5,467 1,650 14,398 3,448 Selling, general and administrative 7,919 2,143 18,851 4,639 Total stock-based compensation expense $ 13,784 $ 3,874 $ 34,357 $ 8,258 Restricted Stock Units The Company began granting restricted stock unit awards (“RSUs”) to employees and other service providers during the first quarter of 2020. RSU activity for the nine months ended September 30, 2020 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2019 — $ — Granted 871,863 70.49 Vested (81,876) 65.91 Cancelled (10,691) 64.97 Outstanding as of September 30, 2020 779,296 $ 71.05 Stock Options Stock options activity for the nine months ended September 30, 2020 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2019 15,918,243 $ 6.82 Granted 1,772,153 78.53 Exercised (4,558,286) 2.48 Cancelled (314,968) 20.30 Outstanding as of September 30, 2020 12,817,142 $ 17.95

Income Tax

Income Tax	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax	Income Tax The Company’s provision for income taxes was $0.6 million and $1.3 million, respectively, for the three and nine months ended September 30, 2020 and $8 thousand and $0.1 million, respectively, for the three and nine months ended September 30, 2019. The Company's effective tax rate was 0.9% and 1.0%, respectively, for the three and nine months ended September 30, 2020 and 0.1% and 0.5%, respectively, for the three and nine months ended September 30, 2019. The provision for income taxes for the three and nine months ended September 30, 2020 consists primarily of foreign taxes. Deferred tax assets generated from the Company’s domestic net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. These provisions are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Net loss $ (65,848) $ (9,603) $ (127,158) $ (24,117) Weighted average shares used in computing net loss per share, basic and diluted 101,341,945 29,184,218 99,058,139 19,904,184 Net loss per share, basic and diluted $ (0.65) $ (0.33) $ (1.28) $ (1.21) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Stock-options to purchase common stock 12,817,142 15,952,177 12,817,142 15,952,177 Shares subject to repurchase 84,375 164,375 84,375 164,375 Restricted stock units 779,296 — 779,296 — Shares committed under ESPP 39,449 2,438 39,449 2,438 Total 13,720,262 16,118,990 13,720,262 16,118,990

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisition of ReadCoor Inc. On October 13, 2020 (the “Closing Date”), the Company completed its acquisition of ReadCoor, Inc., a Delaware corporation (“ReadCoor”), pursuant to the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of October 5, 2020 for a total consideration of $350.0 million in exchange for all outstanding equity interests of ReadCoor, subject to customary purchase price adjustments and holdback arrangements in accordance with the Merger Agreement (the “Merger Consideration”). The Merger Consideration to be paid to the former equity holders of ReadCoor consists, in the aggregate, of $100.0 million in cash (reduced by the amount of any transaction-related expenses, indebtedness and any working capital shortfall of ReadCoor at the Closing Date) and the balance in shares (the “Stock Consideration”) of the Company’s Class A common stock, par value $0.00001 per share (the “Company Common Stock”). The Company issued 1,901,402 shares of Company Common Stock in connection with the Stock Consideration, which were registered for resale in a registration statement on Form S-3 which was automatically effective upon its filing on October 16, 2020. The Merger Agreement contains representations, warranties, covenants, closing conditions and indemnities customary for acquisitions of this type. Lease Agreement

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2019 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Segment Information	Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)
Leases	Leases The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company gives consideration to its credit risk, term of the lease and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and costs of goods sold over the reasonably assured lease term. The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.
Internal-Use Software	Internal-Use Software The Company capitalizes costs incurred to develop internal-use software within fixed assets and commencing from the first quarter of 2020, began capitalizing costs to develop hosting arrangements within other assets in the condensed consolidated
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
Revenue Recognition	Revenue Recognition Commencing on January 1, 2019, the Company recognized revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers. The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The Company began shipping its Chromium Connect instrument during the first quarter of 2020. The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.
Stock-Based Compensation	Stock-Based Compensation The Company’s stock-based compensation relates to stock options, restricted stock units (“RSUs”) and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). Stock-based compensation expense for its stock-based awards are based on their grant date fair value. The Company determines the fair value of RSUs based on the closing value of its stock price listed on Nasdaq at the date of the grant. The Company estimates the fair value of stock option awards granted to employees and directors on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, the Company calculated the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to its IPO and limited publicly available stock price information subsequent to its IPO and therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award. Stock-based compensation expense for nonemployee stock options is measured based on fair market value using the Black-Scholes option pricing model and is recorded as the options vest. Prior to January 1, 2019, nonemployee stock options subject to vesting were revalued periodically over the requisite service period, which was generally the same as the vesting term of the award. From January 1, 2019, the grant date fair market value of nonemployee stock options is recognized in the condensed consolidated statements of operations on a straight-line basis over the requisite service period and forfeitures are recognized as they occur.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. The Company’s participating securities included the Company’s convertible preferred stock, as the holders would have been entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend was paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities, including convertible preferred stock, awards under the Company’s equity compensation plan and common stock warrants. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-2, Leases (Topic 842) . This standard requires substantially all leases to be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. On January 1, 2020, the Company early adopted Topic 842 using the optional transition method by recognizing a cumulative effect adjustment to the opening balance of accumulated deficit as of that date. Results for the three and nine months ended September 30, 2020 are presented under the guidance in Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 – Leases . The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification and to not reassess initial direct costs. The adjustments due to the adoption of Topic 842 related to the recognition of operating lease right-of-use assets and operating lease liabilities for the Company’s existing operating leases. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326) , which requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and provides that credit losses relating to available-for-sale debt securities and accounts receivable should be recorded through an allowance for credit losses. The guidance was amended through various ASUs subsequent to ASU 2016-13. The Company calculates the allowance for credit losses as a percentage of the trade accounts receivable balance based on collection history and current economic trends that we expect will impact the level of credit losses over the life of our receivables. The allowance is re-evaluated on a regular basis and adjusted, as required. Trade accounts receivable are considered past due based on the contractual payment terms. Once a trade account receivable is deemed uncollectible, it is charged against this allowance. The Company early adopted this standard on a modified retrospective basis effective January 1, 2020. The adoption did not have a material impact on the condensed consolidated financial statements. In November 2019, the FASB issued ASU 2019-8, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) , which expands the scope of ASC Topic 718 to provide guidance for share-based payment awards granted to a customer in conjunction with selling goods or services accounted for under Topic 606. The Company early adopted this standard on January 1, 2020, which did not have a material impact on the condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Subtopic 350-40) – Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract , which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. The Company early adopted this standard on a prospective basis effective January 1, 2020. As a result of the adoption of this standard, during the three and nine months ended September 30, 2020, the Company capitalized $0.1 million and $2.8 million, respectively, of implementation costs for enterprise resource planning and related software, Oracle Cloud, which went live during the third quarter of 2020. These costs are recorded within other assets in the condensed consolidated balance sheets and amortized on a straight-line basis over its useful life. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) , which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021. The Company is currently evaluating this standard and the impact it may have on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Disclosure Of Impact Of Topic 842 On Our Condensed Consolidated Balance Sheet	The following table summarizes the impact of Topic 842 on our condensed consolidated balance sheet as of January 1, 2020 (in thousands): December 31, Adjustments due to January 1, 2020 Assets: Operating lease right-of-use assets $ — $ 38,005 $ 38,005 Prepaid expenses and other current assets 8,033 (434) 7,599 Total assets $ 8,033 $ 37,571 $ 45,604 Liabilities: Accrued expenses and other current liabilities $ 24,448 $ (99) $ 24,349 Operating lease liabilities — 3,086 3,086 Deferred rent, noncurrent 16,120 (16,120) — Operating lease liabilities, noncurrent — 50,704 50,704 Total liabilities $ 40,568 $ 37,571 $ 78,139

Asset Acquisition (Tables)

Asset Acquisition (Tables)	9 Months Ended
	Sep. 30, 2020
Asset Acquisition [Abstract]
Schedule of Asset Acquisition	The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process research and development $ 40,637 Intangible assets 801 Other assets and liabilities, net 348 Total net assets acquired $ 41,786

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory was comprised of the following as of the dates indicated (in thousands): September 30, December 31, Purchased materials $ 7,733 $ 6,436 Work in progress 8,475 3,996 Finished goods 8,910 4,838 Inventory $ 25,118 $ 15,270
Schedule of Intangible Assets, Net	Intangible assets, net, which are recorded within other assets in the condensed consolidated balance sheets, consisted of the following (dollars in thousands): September 30, 2020 December 31, 2019 Remaining Useful Life in Years Gross Accumulated Intangibles, Remaining Useful Life in Years Gross Accumulated Intangibles, Technology licenses 14.0 $ 22,504 $ (1,590) $ 20,914 14.7 $ 22,504 $ (440) $ 22,064 Customer relationships 4.1 805 (66) 739 5.9 204 (32) 172 Trademarks 1.1 204 (125) 79 1.9 204 (74) 130 Assembled workforce 4.9 200 (3) 197 — — — Total intangible assets, net $ 23,713 $ (1,784) $ 21,929 $ 22,912 $ (546) $ 22,366
Schedule of Annual Amortization of Intangible Assets	The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2020 (excluding the nine months ended September 30, 2020) $ 455 2021 1,815 2022 1,753 2023 1,723 2024 1,642 Thereafter 14,541 Total $ 21,929
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued payroll and related costs $ 1,146 $ 470 Employee stock purchase program liability 2,614 1,862 Accrued bonus 2,174 6,154 Accrued commissions 2,412 2,473 Accrued acquisition-related compensation 1,481 818 Other 1,362 617 Accrued compensation and related benefits $ 11,189 $ 12,394
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued legal expenses $ 9,984 $ 4,375 Accrued license fee 5,884 6,183 Accrued royalties for licensed technologies 1,811 2,025 Accrued property and equipment 11,874 3,885 Accrued consulting 2,364 1,173 Product warranties 337 467 Customer deposits 1,100 1,304 Taxes payable 1,788 1,087 Other 3,441 3,949 Accrued expenses and other current liabilities $ 38,583 $ 24,448
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): September 30, December 31, Beginning of period $ 467 $ 804 Amounts charged to cost of revenue 438 741 Repairs and replacements (568) (1,078) End of period $ 337 $ 467
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Instruments $ 9,676 $ 10,377 $ 26,108 $ 25,527 Consumables 60,557 49,745 156,149 142,134 Services 1,584 1,085 4,370 2,943 Total revenue $ 71,817 $ 61,207 $ 186,627 $ 170,604
Schedule of Revenue by Geographic Location	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 North America $ 42,363 $ 35,838 $ 102,356 $ 97,293 Europe, Middle East and Africa 15,497 12,136 40,370 36,634 China 8,689 7,046 27,314 22,453 Asia-Pacific 1 5,268 6,187 16,587 14,224 Total revenue $ 71,817 $ 61,207 $ 186,627 $ 170,604 1 Asia-Pacific excludes China which is disclosed separately.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	The maturity of the Company’s operating lease liabilities as of September 30, 2020 is as follows (in thousands): Operating Leases 2020 (excluding the nine months ended September 30, 2020) $ 1,285 2021 9,106 2022 8,136 2023 8,262 2024 8,015 Thereafter 42,681 Total lease payments $ 77,485 Less: imputed interest (15,987) Present value of operating lease liabilities $ 61,498 Operating lease liabilities, current $ 4,955 Operating lease liabilities, noncurrent $ 56,543
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of September 30, 2020: Weighted-average remaining lease term: Operating leases 8.7 years Weighted-average discount rate: Operating leases 5.2 %
Summary of Future Minimum Lease Payments Under the Leases for Facilities	The Company’s future undiscounted lease payments under operating leases (as defined by prior guidance) as of December 31, 2019 are as follow (in thousands): Rent Payments 2020 $ 6,247 2021 7,581 2022 6,794 2023 6,947 2024 7,064 Thereafter 38,346 Total minimum lease payments $ 72,979

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Weighted-Average Fair Value Per Share for Stock Purchased Under ESPP Based on Assumptions	The assumptions used and the resulting weighted-average fair value per share for stock purchased under the ESPP during the nine months ended September 30, 2020 were as follows: Risk-free interest rate 1.85 % Expected volatility 52.18 % Expected term (years) 0.67 Expected dividends 0 % Weighted average grant-date fair value per share $12.60
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Cost of revenue $ 398 $ 81 $ 1,108 $ 171 Research and development 5,467 1,650 14,398 3,448 Selling, general and administrative 7,919 2,143 18,851 4,639 Total stock-based compensation expense $ 13,784 $ 3,874 $ 34,357 $ 8,258
Summary of RSU activity	The Company began granting restricted stock unit awards (“RSUs”) to employees and other service providers during the first quarter of 2020. RSU activity for the nine months ended September 30, 2020 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2019 — $ — Granted 871,863 70.49 Vested (81,876) 65.91 Cancelled (10,691) 64.97 Outstanding as of September 30, 2020 779,296 $ 71.05
Summary of the Company's Stock Option Activity	Stock options activity for the nine months ended September 30, 2020 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2019 15,918,243 $ 6.82 Granted 1,772,153 78.53 Exercised (4,558,286) 2.48 Cancelled (314,968) 20.30 Outstanding as of September 30, 2020 12,817,142 $ 17.95

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Net loss $ (65,848) $ (9,603) $ (127,158) $ (24,117) Weighted average shares used in computing net loss per share, basic and diluted 101,341,945 29,184,218 99,058,139 19,904,184 Net loss per share, basic and diluted $ (0.65) $ (0.33) $ (1.28) $ (1.21)
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Stock-options to purchase common stock 12,817,142 15,952,177 12,817,142 15,952,177 Shares subject to repurchase 84,375 164,375 84,375 164,375 Restricted stock units 779,296 — 779,296 — Shares committed under ESPP 39,449 2,438 39,449 2,438 Total 13,720,262 16,118,990 13,720,262 16,118,990

Description of Business and B_2

Description of Business and Basis of Presentation - Additional Information (Detail) - Common Class A - USD ($) $ / shares in Units, $ in Millions	Sep. 10, 2020	Sep. 16, 2019
Subsidiary, Sale of Stock [Line Items]
Proceeds from initial public offer		$ 410.8
IPO
Subsidiary, Sale of Stock [Line Items]
Common stock new issue shares (in shares)		11,500,000
IPO offer price per share (in dollars per share)		$ 39
Proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs		$ 37.7
IPO | Underwriter Offer
Subsidiary, Sale of Stock [Line Items]
Common stock new issue shares (in shares)		1,500,000
Follow-on Public Offering
Subsidiary, Sale of Stock [Line Items]
Common stock new issue shares (in shares)	4,600,000
IPO offer price per share (in dollars per share)	$ 110
Proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs	$ 23.8
Aggregate net proceeds after deduction of offering costs	$ 482.2
Follow-on Public Offering | Underwriter Offer
Subsidiary, Sale of Stock [Line Items]
Common stock new issue shares (in shares)	600,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)segment	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2020USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of operating segments | segment			1
Impairment of long lived assets	$ 0	$ 0	$ 0	$ 0
Revenue recognition, payment due period			45 days
Operating lease right-of-use assets	45,379,000		$ 45,379,000			$ 38,005,000
Operating lease liabilities	61,498,000		61,498,000			$ 53,800,000
Accounting Standards Update 2018-15
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capitalized costs due to adoption of standard	100,000		2,800,000
Fair Value, Inputs, Level 1 | Money Market Funds
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fair value of money market instruments	$ 717,700,000		717,700,000		$ 398,500,000
Unrealized gains (losses) on money market instruments			$ 0		$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of the Impact of Topic 842 on our Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Jan. 01, 2020	Sep. 30, 2020	Dec. 31, 2019
Disclosure Of Impact Of Topic 842 On Our Condensed Consolidated Balance Sheet [Line Items]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201602Member
Assets:
Operating lease right-of-use assets	$ 38,005	$ 45,379
Prepaid expenses and other current assets	7,599	11,083	$ 8,033
Total assets	45,604	1,042,544	605,923
Liabilities:
Accrued expenses and other current liabilities	24,349	38,583	24,448
Operating lease liabilities	3,086	4,976
Deferred rent, noncurrent			16,120
Operating lease liabilities, noncurrent	50,704	56,618
Total liabilities	78,139	$ 217,464	185,840
Previously Reported
Assets:
Prepaid expenses and other current assets			8,033
Total assets			8,033
Liabilities:
Accrued expenses and other current liabilities			24,448
Deferred rent, noncurrent			16,120
Total liabilities			$ 40,568
Adjustments due to the adoption of Topic 842
Assets:
Operating lease right-of-use assets	38,005
Prepaid expenses and other current assets	(434)
Total assets	37,571
Liabilities:
Accrued expenses and other current liabilities	(99)
Operating lease liabilities	3,086
Deferred rent, noncurrent	(16,120)
Operating lease liabilities, noncurrent	50,704
Total liabilities	$ 37,571

Asset Acquisition - Additional

Asset Acquisition - Additional Information (Details) - CartaNA - USD ($) $ in Thousands	Aug. 21, 2020	Sep. 30, 2020
Asset Acquisition [Line Items]
Cash payments for asset acquisition	$ 41,800
Transaction costs	600
Cash acquired	1,500
In-process research and development	40,637
Intangible assets	$ 801	$ 800

Asset Acquisition - Schedule of

Asset Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details) - CartaNA - USD ($) $ in Thousands	Aug. 21, 2020	Sep. 30, 2020
Asset Acquisition [Line Items]
In-process research and development	$ 40,637
Intangible assets	801	$ 800
Other assets and liabilities, net	348
Total net assets acquired	$ 41,786

Other Financial Statement Inf_3

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 7,733	$ 6,436
Work in progress	8,475	3,996
Finished goods	8,910	4,838
Inventory	$ 25,118	$ 15,270

Other Financial Statement Inf_4

Other Financial Statement Information - Intangible Assets, Net (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 23,713	$ 22,912
Accumulated Amortization	(1,784)	(546)
Intangibles, Net	$ 21,929	$ 22,366
Technology licenses
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	14 years	14 years 8 months 12 days
Gross Carrying Amount	$ 22,504	$ 22,504
Accumulated Amortization	(1,590)	(440)
Intangibles, Net	$ 20,914	$ 22,064
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	4 years 1 month 6 days	5 years 10 months 24 days
Gross Carrying Amount	$ 805	$ 204
Accumulated Amortization	(66)	(32)
Intangibles, Net	$ 739	$ 172
Trademarks
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	1 year 1 month 6 days	1 year 10 months 24 days
Gross Carrying Amount	$ 204	$ 204
Accumulated Amortization	(125)	(74)
Intangibles, Net	$ 79	$ 130
Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	4 years 10 months 24 days
Gross Carrying Amount	$ 200	$ 0
Accumulated Amortization	(3)	0
Intangibles, Net	$ 197	$ 0

Other Financial Statement Inf_5

Other Financial Statement Information - Annual Amortization of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2020 (excluding the nine months ended September 30, 2020)	$ 455
2021	1,815
2022	1,753
2023	1,723
2024	1,642
Thereafter	14,541
Intangibles, Net	$ 21,929	$ 22,366

Other Financial Statement Inf_6

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 1,146	$ 470
Employee stock purchase program liability	2,614	1,862
Accrued bonus	2,174	6,154
Accrued commissions	2,412	2,473
Accrued acquisition-related compensation	1,481	818
Other	1,362	617
Accrued compensation and related benefits	$ 11,189	$ 12,394

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jan. 01, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal expenses	$ 9,984		$ 4,375
Accrued license fee	5,884		6,183
Accrued royalties for licensed technologies	1,811		2,025
Accrued property and equipment	11,874		3,885
Accrued consulting	2,364		1,173
Product warranties	337		467
Customer deposits	1,100		1,304
Taxes payable	1,788		1,087
Other	3,441		3,949
Accrued expenses and other current liabilities	$ 38,583	$ 24,349	$ 24,448

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 467	$ 804
Amounts charged to cost of revenue	438	741
Repairs and replacements	(568)	(1,078)
End of period	$ 337	$ 467

Other Financial Statement Inf_9

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Concentration Risk [Line Items]
Transaction price allocated to remaining performance obligations	$ 5,000		$ 5,000
Contract liability	5,000		5,000		$ 4,100
Deferred revenue, current	3,775		3,775		$ 3,297
Contract with customer, liability, revenue recognized	$ 700		$ 2,800
Revenue | Geographic Concentration Risk | UNITED STATES
Concentration Risk [Line Items]
Percentage of revenue	57.00%	57.00%	53.00%	55.00%

Other Financial Statement In_10

Other Financial Statement Information - Revenue Recognition (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01	Sep. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations percentage	75.00%
Expected period of revenue recognition	12 months

Other Financial Statement In_11

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from External Customer [Line Items]
Revenue	$ 71,817	$ 61,207	$ 186,627	$ 170,604
Instruments
Revenue from External Customer [Line Items]
Revenue	9,676	10,377	26,108	25,527
Consumables
Revenue from External Customer [Line Items]
Revenue	60,557	49,745	156,149	142,134
Services
Revenue from External Customer [Line Items]
Revenue	$ 1,584	$ 1,085	$ 4,370	$ 2,943

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 71,817	$ 61,207	$ 186,627	$ 170,604
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	42,363	35,838	102,356	97,293
Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	15,497	12,136	40,370	36,634
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	8,689	7,046	27,314	22,453
Asia-Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 5,268	$ 6,187	$ 16,587	$ 14,224

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Jun. 18, 2020	Feb. 20, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ (1,521,000)	$ 0
Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity	$ 25,000,000
Line of credit facility available as a percentage of receivables	80.00%
Line of credit facility, termination fee	$ 300,000
Line of credit, outstanding			$ 0		$ 0		$ 0
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Debt instrument spread on variable rate	0.25%
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Debt instrument spread on variable rate	4.50%
Tranche A | Term Loan
Debt Instrument [Line Items]
Early payment of debt		$ 30,500,000
Early payment of debt principal amount		28,300,000
Early payment, term payment		1,800,000
Early payment of debt termination fees		300,000
Early payment of debt interest amount		100,000
Loss on extinguishment of debt		$ 1,500,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) € in Thousands

Nov. 12, 2020USD ($)

Oct. 30, 2020petition

Oct. 15, 2020

Aug. 10, 2020USD ($)

Apr. 27, 2020petition

Apr. 16, 2020EUR (€)

Dec. 18, 2019

Nov. 12, 2020USD ($)

Oct. 31, 2019USD ($)petition

Aug. 31, 2019USD ($)

Jul. 31, 2019USD ($)

Jun. 30, 2018USD ($)

Sep. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Dec. 31, 2018USD ($)

Sep. 30, 2020USD ($)

Sep. 30, 2020EUR (€)

Sep. 30, 2019USD ($)

Dec. 31, 2018USD ($)

Aug. 31, 2020petition

Jun. 24, 2020petition

Mar. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Sep. 13, 2019USD ($)

Loss Contingencies [Line Items]

Operating lease costs

$ 2,100,000

$ 6,100,000

Variable lease costs

19,000

200,000

Operating lease payment

5,100,000

Purchase price

15,327,000

$ 36,186,000

Accrual provision

332,000

$ 0

956,000

1,360,000

Restricted cash

59,451,000

59,451,000

$ 0

Percentage of accused microfluidic chips for payment of bond

3.00%

Number of petitions for inter partes review | petition

4

4

Payment of litigation settlement expense | €

€ 2,800

Number of petitions filed challenging validity of patent | petition

2

2

Subsequent Event

Loss Contingencies [Line Items]

Number of petitions for inter partes review | petition

2

Pleasanton, California Property

Loss Contingencies [Line Items]

Purchase price

$ 29,800,000

Contingency period

74 days

Additional days for the contingency period

30 days

Closing of sale after contingency period

31 days

Pleasanton, California Property | Subsequent Event

Loss Contingencies [Line Items]

Additional days for the contingency period

14 days

Notice of satisfaction deposit

$ 800,000

Milestone Payment

Loss Contingencies [Line Items]

Other commitment

$ 5,000,000

BD Entities | Intellectual Property

Loss Contingencies [Line Items]

Purchase price of asset acquired

$ 25,000,000

Annual payments

$ 6,250,000

Payment period

4 years

Bio Rad

Loss Contingencies [Line Items]

Company bear the legal cost of court | €

€ 61,000

Bio RadLaboratories Inc

Loss Contingencies [Line Items]

Damages awarded

$ 35,000,000

$ 24,000,000

Royalty percentage on sales

15.00%

15.00%

Royalty expense

$ 7,400,000

Loss contingency

77,600,000

$ 38,000,000

77,600,000

$ 38,000,000

Bond amount

$ 52,000,000

$ 52,000,000

Potential increase in bond amount

61,000,000

Potential decrease in bond amount

$ 35,000,000

Restricted cash

59,400,000

59,400,000

Bio RadLaboratories Inc | Subsequent Event | Forecast

Loss Contingencies [Line Items]

Damages awarded

$ 34,500,000

Post judgment interest

$ 800,000

Bio RadLaboratories Inc | Assets Held In Trust

Loss Contingencies [Line Items]

Cash collateral

$ 45,000,000

Bio RadLaboratories Inc | Operating Expense

Loss Contingencies [Line Items]

Accrual provision

$ 30,600,000

Pre and post judgment interest

300,000

0

900,000

1,400,000

Bio RadLaboratories Inc | Cost of Sales

Loss Contingencies [Line Items]

Royalty expense

$ 2,000,000

$ 7,200,000

$ 7,900,000

$ 23,100,000

Minimum

Loss Contingencies [Line Items]

Operating lease term

2 years

2 years

Maximum

Loss Contingencies [Line Items]

Operating lease term

11 years

11 years

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jan. 01, 2020
Operating Leases
2020 (excluding the nine months ended September 30, 2020)	$ 1,285
2021	9,106
2021	8,136
2022	8,262
2023	8,015
Thereafter	42,681
Total lease payments	77,485
Less: imputed interest	(15,987)
Present value of operating lease liabilities	61,498	$ 53,800
Operating lease liabilities, current	4,955
Operating lease liabilities, noncurrent	$ 56,543

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term, operating leases	8 years 8 months 12 days
Weighted-average discount rate, operating leases	5.20%

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Operating Leases (Details) $ in Thousands	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 6,247
2021	7,581
2022	6,794
2023	6,947
2024	7,064
Thereafter	38,346
Total minimum lease payments	$ 72,979

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Common stock shares issued (in shares)	105,599,976	105,599,976	96,241,596
Common stock shares outstanding (in shares)	105,599,976	105,599,976	96,241,596
Shares Converted From Class B to Class A
Class of Stock [Line Items]
Conversion of stock, shares converted (in shares)	2,153,783	47,558,717
Common Class A
Class of Stock [Line Items]
Common stock shares issued (in shares)	77,888,613	77,888,613
Common stock shares outstanding (in shares)	77,888,613	77,888,613
Common Class B
Class of Stock [Line Items]
Common stock shares issued (in shares)	27,710,713	27,710,713
Common stock shares outstanding (in shares)	27,710,713	27,710,713

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - Common Class A - shares	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
10x Genomics, Inc. 2012 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable (in shares)	10,510,200	10,510,200
2019 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable (in shares)	8,294,784	8,294,784
Common stock reserved for issuance (in shares)	11,000,000	11,000,000
Shares issuable in connection with outstanding awards (in shares)	3,086,238	3,086,238
2019 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	1,881,782	1,881,782	2,000,000
Share-based compensation arrangement percent		85.00%
Shares issued in period for previously outstanding awards (in shares)		118,218
Common stock purchased under ESPP (in shares)	0		0

Equity Incentive Plans - Weight

Equity Incentive Plans - Weighted-Average Fair Value Per Share Under ESPP (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value per share (in dollars per share)	$ 71.05	$ 0
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.85%
Expected volatility	52.18%
Expected term (years)	8 months 1 day
Expected dividends	0.00%
Weighted average grant-date fair value per share (in dollars per share)	$ 12.60

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 13,784	$ 3,874	$ 34,357	$ 8,258
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	398	81	1,108	171
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	5,467	1,650	14,398	3,448
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 7,919	$ 2,143	$ 18,851	$ 4,639

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of RSU Activity (Detail)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Restricted Stock Units, Beginning balance (in shares) | shares	0
Restricted Stock Units, Granted (in shares) | shares	871,863
Restricted Stock Units, Vested (in shares) | shares	(81,876)
Restricted Stock Units, Cancelled (in shares) | shares	(10,691)
Restricted Stock Units, Ending balance (in shares) | shares	779,296
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares	$ 0
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	70.49
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	65.91
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	64.97
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares	$ 71.05

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Company's Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding stock options, Beginning balance (in shares) | shares	15,918,243
Outstanding stock options - Granted (in shares) | shares	1,772,153
Outstanding stock options - Exercised (in shares) | shares	(4,558,286)
Outstanding stock options - Cancelled (in shares) | shares	(314,968)
Outstanding stock options, Ending balance (in shares) | shares	12,817,142
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-average exercise price - Beginning balance (in dollars per share) | $ / shares	$ 6.82
Weighted-average exercise price - Granted (in dollars per share) | $ / shares	78.53
Weighted-average exercise price - Exercised (in dollars per share) | $ / shares	2.48
Weighted-average exercise price - Cancelled (in dollars per share) | $ / shares	20.30
Weighted-average exercise price - Ending balance (in dollars per share) | $ / shares	$ 17.95

Income Tax - Additional Informa

Income Tax - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 585	$ 8	$ 1,305	$ 110
Effective tax rate	0.90%	0.10%	1.00%	0.50%

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ (65,848)	$ (40,167)	$ (21,143)	$ (9,603)	$ (10,878)	$ (3,636)	$ (127,158)	$ (24,117)
Weighted average shares used in computing net loss per share, basic and diluted (in shares)	101,341,945			29,184,218			99,058,139	19,904,184
Net loss per share, basic and diluted (in dollars per share)	$ (0.65)			$ (0.33)			$ (1.28)	$ (1.21)

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	13,720,262	16,118,990	13,720,262	16,118,990
Stock-options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	12,817,142	15,952,177	12,817,142	15,952,177
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	84,375	164,375	84,375	164,375
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	779,296	0	779,296	0
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	39,449	2,438	39,449	2,438

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands	Oct. 13, 2020USD ($)shares	Nov. 06, 2020USD ($)ft²	Sep. 30, 2020USD ($)$ / shares	Dec. 31, 2019$ / shares
Subsequent Event [Line Items]
Common stock, par value (in USD per share) | $ / shares			$ 0.00001	$ 0.00001
Total lease payments			$ 77,485
Common Class A
Subsequent Event [Line Items]
Common stock, par value (in USD per share) | $ / shares			$ 0.00001
Subsequent Event | Additional office building
Subsequent Event [Line Items]
Real estate property, area | ft²		145,000
Total lease payments		$ 60,800
Subsequent Event | ReadCoor Inc.
Subsequent Event [Line Items]
Consideration transferred	$ 350,000
Payment, cash	$ 100,000
Subsequent Event | ReadCoor Inc. | Common Class A
Subsequent Event [Line Items]
Common stock issued (in shares) | shares	1,901,402